Novartis Takes Aim At Systemic Mastocytosis With Midostaurin

Novartis AG's novel anticancer midostaurin is looking promising in the rare indication of advanced systemic mastocytosis given positive data from a pivotal Phase II study just published in the New England Journal of Medicine.